Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial. in HemaSphere / Hemasphere. 2026 May 20;10(5):e70393. doi: 10.1002/hem3.70393. eCollection 2026 May.

2026
AOU Alessandria

Tipo pubblicazione

Journal Article

Autori/Collaboratori (41)Vedi tutti...

Maher N
Division of Hematology, Department of Translational Medicine Università del Piemonte Orientale and AOU Maggiore della Carità di Novara Novara Italy.
Moia R
Department of Translational Medicine, SCDU Ematologia AO SS Antonio e Biagio E Cesare Arrigo Università del Piemonte Orientale Alessandria Italy.
Almasri M
Division of Hematology, Department of Translational Medicine Università del Piemonte Orientale and AOU Maggiore della Carità di Novara Novara Italy.

et alii...

Abstract

Whether clonal hematopoiesis (CH) in follicular lymphoma (FL) patients affects clinical outcome or is merely a bystander phenomenon is unclear. We leveraged the Phase III Fondazione Italiana Linfomi FOLL12 trial, which treated patients with advanced-stage FL with R-CHOP or R-Bendamustine, to evaluate the role of myeloid CH at baseline and after chemoimmunotherapy (CIT). A total of 528 serial blood samples from 242 FL were analyzed by CAPP-Seq. At baseline, CH occurred in 35.5% patients with DNMT3A (N?=?41, 16.9%) and TET2 (N?=?29, 12.0%) being the most frequently mutated genes. After a median follow-up of 8.2 years, CH at baseline did not impact progression-free survival (PFS), overall survival (OS), or risk of transformation (P?=?0.660, P?=?0.230, and P?=?0.584, respectively), but instead

Accesso banca dati bibliografica

PMID : 42256545

DOI : 10.1002/hem3.70393